10mg Chewable Methylphenidate for ADHD
For children 6 years and older with ADHD, start methylphenidate chewable tablets at 10mg twice daily (before breakfast and lunch), titrate weekly by 5-10mg increments based on response and tolerability, with a maximum daily dose of 60mg. 1
Initial Prescribing
Patient Selection
- Age requirement: 6 years or older 1
- Diagnosis: Must meet DSM-5 criteria for ADHD 2
- Severity assessment: Medication is appropriate for moderate-to-severe ADHD with dysfunction in multiple settings 2
- IQ requirement: Normal intellectual functioning (IQ > 70) 3
Pre-Treatment Screening (Critical)
Before prescribing, you must screen for:
- Cardiac contraindications: Known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease are absolute contraindications 1
- Psychiatric risk factors: Screen for bipolar disorder, psychosis, or family history of these conditions 1
- Substance use: Particularly in adolescents - active substance use requires subspecialist consultation before initiating 2
- Hypersensitivity: Previous allergic reactions to methylphenidate 1
- MAOI use: Contraindicated if patient is taking or has taken MAOIs within 14 days 1
Dosing Algorithm
Starting Dose
- Initial: 10mg twice daily (morning and midday, 30-45 minutes before meals) 1
- Alternative lower start: 5mg twice daily for younger children (6-8 years) or those with concerns about tolerability 4
Titration Schedule
- Frequency: Weekly adjustments 1
- Increments: Increase by 5-10mg per day based on efficacy and tolerability 1
- Target range: Most children optimize between 20-60mg/day 4
- 6-8 year-olds: Average final dose ~40mg/day
- 11-12 year-olds: Average final dose ~45mg/day 4
- Maximum: 60mg/day - doses above this are not recommended 1
Practical Titration Example
- Week 1: 10mg twice daily (20mg/day total)
- Week 2: 15mg twice daily (30mg/day total) if tolerated
- Week 3: 20mg twice daily (40mg/day total) if needed
- Continue weekly until optimal response or maximum dose reached
Administration
Timing
- Twice daily dosing: Before breakfast and lunch (30-45 minutes before meals) 1
- Duration of effect: Chewable formulations provide coverage for approximately 8 hours post-dose 5
- For adolescent drivers: Consider longer-acting formulations or late-afternoon short-acting doses for symptom control while driving 2
Formulation Advantages
The chewable tablet offers:
- Solution for patients with swallowing difficulties 6, 7
- Flexible dosing options 8
- Rapid onset at 0.75-2 hours with efficacy through 8 hours 5
Monitoring Requirements
Baseline Assessment
- Height and weight
- Blood pressure and pulse
- Cardiac evaluation if any history suggests cardiac disease 1
- Psychiatric assessment including suicidality screening 1
Ongoing Monitoring
At each visit (especially during titration):
- Growth parameters: Height and weight - growth suppression is a known effect requiring potential treatment interruption 6, 1
- Cardiovascular: Blood pressure and pulse regularly 6, 1
- Psychiatric symptoms: Monitor for new or worsening psychotic symptoms, mania, aggression, or suicidal ideation 1
- Medication adherence: Assess regularly, as non-adherence is common 6
- Diversion risk: Particularly in adolescents - monitor prescription refill patterns 2
Efficacy Assessment
- Use standardized rating scales (e.g., ADHD-RS-IV) from teachers and parents 4
- Expect progressive symptom improvement over 5-6 weeks of optimization 4
- Minimal clinically relevant improvement is 6.6 points on ADHD-RS 3
Common Adverse Events to Anticipate
- Decreased appetite (most common)
- Insomnia
- Upper abdominal pain
- Headache
- Mood swings/irritability
- Dysgeusia (altered taste)
Cardiovascular:
- Increased blood pressure and pulse (monitor regularly) 6
Growth effects:
Special Considerations
Preschool Children (Under 6 Years)
- Not recommended as first-line 2
- Behavioral interventions should be primary treatment 6
- If medication necessary: Only for severe cases with 9+ months of symptoms, dysfunction in multiple settings, and failure of behavioral therapy 2
- Use lower starting doses with smaller increments due to slower metabolism 2
Adolescents
- Higher diversion risk: Consider non-stimulant alternatives (atomoxetine, guanfacine, clonidine) if substance use concerns exist 2
- Driving safety: Ensure medication coverage during driving hours 2
- Substance use screening: Mandatory before initiation 2
Comorbidities
- Anxiety or lower socioeconomic status: Combined behavioral therapy + medication shows superior outcomes 2
- Tics/Tourette's: Assess family history; monitor for emergence or worsening 1
- Glaucoma: Use with extreme caution; requires ophthalmology evaluation 1
Treatment Duration and Reassessment
- Periodic reassessment: Consider medication-free intervals to determine continued need 6
- Long-term efficacy: Evidence supports continued benefit with long-term use, though periodic evaluation is essential 6
- Treatment adjustments: Changes in regimen are the rule, not the exception, due to growth, changing symptoms, or psychosocial factors 6
Critical Pitfalls to Avoid
- Failing to screen for cardiac disease: Sudden death has occurred in patients with undiagnosed heart conditions 1
- Missing psychiatric comorbidities: New psychotic or manic symptoms can emerge; screen beforehand 1
- Inadequate monitoring: Growth, blood pressure, and psychiatric symptoms require regular assessment 6, 1
- Ignoring adherence issues: Non-adherence is common and undermines treatment effectiveness 6
- Overlooking diversion in adolescents: Methylphenidate is a controlled substance with abuse potential 2, 1
Combination Treatment
Behavioral therapy should be provided alongside medication 2, 6:
- Combined treatment shows advantages for academic performance, conduct problems, and parent/teacher satisfaction 2
- Particularly beneficial when ADHD is comorbid with anxiety or in lower socioeconomic environments 2
- Psychosocial interventions address functional deficits that medication alone may not fully resolve 6
Abuse and Misuse Warning
Methylphenidate is a Schedule II controlled substance with high potential for abuse and misuse 1:
- Assess each patient's risk before prescribing
- Educate families about proper storage and disposal
- Monitor for signs of misuse or diversion throughout treatment
- Physical dependence can develop even with prescribed use 1